Navigation Links
VioQuest Pharmaceuticals Announces Data Presentation for Its Akt,Inhibitor VQD-002, at American Association for Cancer Research,Annual Meeting

rrent expectations, forecasts and assumptions that are subject to risks and uncertainties, which could cause actual outcomes and results to differ materially from these statements. Among other things, there can be no assurances that the FDA will approve VioQuest's planned NDA submission relating to Lenocta(TM) for the treatment of leishmaniasis, and even if approved, there is no assurance that VioQuest will be able to successfully commercialize Lenocta(TM) for the treatment of leishmaniasis or any other indication, or that VioQuest will receive any proceeds in connection with a sale or other disposition of its Chiral Quest division. Other risks and uncertainties include the possibility that the results of clinical trials will not support VioQuest's claims, the possibility that VioQuest's development efforts relating to its product candidates, including Lenocta(TM) and VQD-002, will not be successful, the inability to obtain regulatory approval of VioQuest's product candidates, VioQuest's reliance on third-party researchers to develop its product candidates, its lack of experience in developing and commercializing pharmaceutical products, and the possibility that its licenses to develop and commercialize its product candidates may be terminated. Additional risks are described in VioQuest's Annual Report on Form 10-KSB for the year ended December 31, 2006. VioQuest assumes no obligation and does not intend to update these forward-looking statements, except as required by law.

    Contact information:

    Daniel Greenleaf                     Brian Lenz

    President and CEO                    Chief Financial Officer

    908-766-4400 ext. 115                908-766-4400 ext. 117

          

dan.greenleaf@vioquestpharm.com brian.lenz@vioquestpharm.com

CONTACT: Daniel Greenleaf, President and CEO, +1-908-766-4400
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
2. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
3. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
4. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
5. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
6. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
7. Pro-Pharmaceuticals Updates Progress of Clinical Trials & Davanat 505 (b)(2) Filings
8. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
9. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
10. Cyclacel Pharmaceuticals Announces Results of Phase II Seliciclib Combination Studies
11. Arisaph Pharmaceuticals Announces Results of its Potent Smart DPP-4 Inhibitor, ARI-2243, at the ADA
Post Your Comments:
(Date:1/15/2014)... today announced it has established a relief fund ... that has gripped much of the nation. AARP and its ... support these emergency relief efforts AARP and AARP Foundation will ... to $500,000 in aid. The matching program will be administered ...
(Date:1/15/2014)... WORTH, Texas , Jan. 15, 2014  Humberto C. ... Dermatology Achievement Award" from the Journal of Drugs ... Aesthetic & Clinical Conference (ODAC). The event is January 17-20, ... Florida . The ODAC ...
(Date:1/15/2014)... , Jan. 15, 2014 MultiCell Technologies, Inc. (OTC ... U.S. provisional patent application concerning composition of matter, biological ... targeted tumor cell death.  This patent ... double stranded RNA molecules (VSRNAs) which interfere with the ...
Breaking Medicine Technology:AARP Foundation Establishes Winter Relief Fund for Older Adults Suffering from the Severe Cold Weather 2AARP Foundation Establishes Winter Relief Fund for Older Adults Suffering from the Severe Cold Weather 3Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 2Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 3Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 4MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 2MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 3
... evaluates the efficacy of new device for detecting polyps that ... ... Oct. 7 At the American College of,Gastroenterology Annual Scientific ... presented results from a,multi-institutional clinical study that evaluated the efficacy ...
... Results of FLEXX Trial Presented at the Osteoarthritis ... Oct. 7 Ferring Pharmaceuticals Inc.,recently presented results ... showing that EUFLEXXA(R) (1% sodium hyaluronate), a highly ... acid,(IA-HA), is superior to intra-articular saline (IA-saline) for ...
Cached Medicine Technology:National Study Presented at ACG 2008 Confirms New Device Functions Like 'Rear-View Mirror' to Provide Improved View of the Colon 2National Study Presented at ACG 2008 Confirms New Device Functions Like 'Rear-View Mirror' to Provide Improved View of the Colon 3National Study Presented at ACG 2008 Confirms New Device Functions Like 'Rear-View Mirror' to Provide Improved View of the Colon 4National Study Presented at ACG 2008 Confirms New Device Functions Like 'Rear-View Mirror' to Provide Improved View of the Colon 5Study Shows EUFLEXXA(R) Patients Report Significant Improvements in Osteoarthritis of the Knee Pain over a Six Month Period 2Study Shows EUFLEXXA(R) Patients Report Significant Improvements in Osteoarthritis of the Knee Pain over a Six Month Period 3Study Shows EUFLEXXA(R) Patients Report Significant Improvements in Osteoarthritis of the Knee Pain over a Six Month Period 4
(Date:7/9/2014)... There has been a sharp increase in the ... using MyChart, the online, interactive service that allows patients ... healthcare providers, schedule appointments, and renew prescriptions. , Over ... MyChart each year increased five-fold, while the ... 10-fold, according to a study by Dr. David ...
(Date:7/9/2014)... The National Institute of Allergy and Infectious Diseases ... has launched an early-stage clinical trial of CRS3123, ... Clostridium difficile ( C. difficile ) infection. ... agent that inhibits C. difficile growth while sparing ... will enroll up to 30 healthy men and ...
(Date:7/9/2014)... , , , , ... , , , AUDIO: ... and approximately 30cm from the bullet... , , Click here ... , , , , , ... , , , , , University of Southampton researchers, with assistance from the Ministry ...
(Date:7/8/2014)... The UCLA Program in Memory Restoration has been awarded ... Projects Agency (DARPA) for a four -year project aiming ... UCLA team of experts in neurosurgery, engineering, neurobiology, psychology ... test a memory prosthesis in the brain. , Memory ... of the brain encode information, store it and retrieve ...
(Date:7/8/2014)... have discovered a biomarker that could give expecting mothers ... reliably predict that a pregnant woman may develop preeclampsia, ... pregnancy. , Preeclampsia is a cardiovascular disorder generally occurring ... delivery, creating immediate and potentially lifelong risks to both ... protein in the urine, and is typically diagnosed in ...
Breaking Medicine News(10 mins):Health News:MyChart use skyrocketing among cancer patients, UT Southwestern study finds 2Health News:MyChart use skyrocketing among cancer patients, UT Southwestern study finds 3Health News:NIH launches Phase I clinical trial of novel drug to treat Clostridium difficile infection 2Health News:Fit for the frontline? New study identifies the hearing requirements of British soldiers 2Health News:Fit for the frontline? New study identifies the hearing requirements of British soldiers 3Health News:Fit for the frontline? New study identifies the hearing requirements of British soldiers 4Health News:Fit for the frontline? New study identifies the hearing requirements of British soldiers 5Health News:Fit for the frontline? New study identifies the hearing requirements of British soldiers 6Health News:Fit for the frontline? New study identifies the hearing requirements of British soldiers 7Health News:DARPA awards UCLA $15 million to restore lost memory 2Health News:DARPA awards UCLA $15 million to restore lost memory 3Health News:UI researchers find early predictor for preeclampsia 2Health News:UI researchers find early predictor for preeclampsia 3
... 15 The Endovascular Forum, Inc. (EVF), an ... Cardiovascular Angiography,and Interventions (SCAI), announced a collaboration to ... complex clinical skills,development in Cardiovascular medicine. The partnership ... developing a new generation of tools for,physicians to ...
... reform should make improved quality and efficiency paramount and move ... as a shared national resource, DMAA: The Care Continuum Alliance ... "The time is now to change the current ... Health Care Reform." DMAA represents organizations and individuals dedicated to ...
... shows extent, impact of family caregiving in state. , ... to family members or loved ones need information on available resources ... home & community-based services be increased, according to a survey released ... are or have been caregivers. , , ...
... of the men who took part in the prostate cancer ... diagnosed with the disease and the majority of those were ... the December issue of the urology journal BJU International ... from 55 to 74 took part in the multi-centre Prostate, ...
... Achievements of Past Century Include Major Milestones in the Advancement ... , , ALEXANDRIA, Va., Dec. ... its Centennial Year: "Celebrating the Legacy, Forging the Future." ... story of one person who turned a personal struggle with ...
... Study Led by M.D. Anderson Cancer Center To Evaluate Surgery ... ... Fla. (PRWEB) December 15, 2008 -- CyberKnife Center of Palm Beach, ... enrolled in the landmark study comparing traditional surgery and CyberKnife® radiosurgery ...
Cached Medicine News:Health News:The Endovascular Forum, Inc. and the Society for Cardiovascular Angiography and Interventions Partner to Extend the Influence of Electronic Medical Care Innovation to Cardiovascular Medicine Through www.EndoVascular.Org, a Global, Multi-disciplinary Care 2Health News:The Endovascular Forum, Inc. and the Society for Cardiovascular Angiography and Interventions Partner to Extend the Influence of Electronic Medical Care Innovation to Cardiovascular Medicine Through www.EndoVascular.Org, a Global, Multi-disciplinary Care 3Health News:The Endovascular Forum, Inc. and the Society for Cardiovascular Angiography and Interventions Partner to Extend the Influence of Electronic Medical Care Innovation to Cardiovascular Medicine Through www.EndoVascular.Org, a Global, Multi-disciplinary Care 4Health News:DMAA Health Care Reform Principles Call for Focus on Quality, Efficiency 2Health News:DMAA Health Care Reform Principles Call for Focus on Quality, Efficiency 3Health News:Caregivers in Maryland Call for Increased Funding, Support 2Health News:USA's largest ever prostate cancer screening program shows high compliance and consistent results 2Health News:USA's largest ever prostate cancer screening program shows high compliance and consistent results 3Health News:Mental Health America Celebrates 100 Years of Mental Health Advocacy and Support 2Health News:Mental Health America Celebrates 100 Years of Mental Health Advocacy and Support 3Health News:First Patient from CyberKnife Center of Palm Beach Enrolled in Worldwide Landmark Study of Operable Lung Cancer Patients 2Health News:First Patient from CyberKnife Center of Palm Beach Enrolled in Worldwide Landmark Study of Operable Lung Cancer Patients 3
Enzyme Immunoassay of -Thromboglobulin Antigen by ELISA Method, 96 tests....
HbA1c / HbCalibrator...
Heparin-Platelet Factor 4 Induced Antibody...
Multi-constituent Calibration Plasma for Functional Assays of Coagulation Parameters on STA© Analyzers....
Medicine Products: